CORRECTED: PTAB Rejects Mylan's Challenge To Gilead's Viread Patent
The Patent Trial and Appeal Board on Tuesday rejected Mylan Pharmaceuticals Inc.'s petition for inter partes review of a Gilead Sciences Inc. patent for its antiviral treatment Viread, ruling that Mylan...To view the full article, register now.
Already a subscriber? Click here to view full article